WELLBUTRIN

all catalysts(0)

nothing on the calendar yet

News(3)

• Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity
  As Xenon Pharmaceuticals announced that azetukalner has reached the FDA for focal seizures, the company also disclosed the emergence of psychosis adverse events in psychiatric trials of the drug, t…
  biospace · 11d ago
• Xenon pauses phase 3 depression trials after psychosis events
  The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.
  fiercebiotech · 12d ago
• Opinion: RFK Jr.’s antidepressant deprescribing push gets one thing right — and others dangerously wrong
  “Deprescribing requires gradual tapering, psychological support, careful risk stratification, and accessible alternatives — none of which Kennedy’s initiative provides at scale.”
  stat · 4mo ago